Alexander A. Fitzpatrick - 18 Feb 2022 Form 4 Insider Report for Evofem Biosciences, Inc. (EVFM)

Reporting relationship: General Counsel and Secretary
Issuer ticker: EVFM
Reported as of: 18 Feb 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Feb 2022, 15:08:06 UTC
Prior SEC filing: 04 Jan 2022
Next SEC filing: 01 Dec 2022
Source filing: View source filing
Reporting owner signature: /s/ Justin J. File, attorney-in-fact

Key filing fact

Alexander A. Fitzpatrick filed Form 4 for Evofem Biosciences, Inc. (EVFM) on 23 Feb 2022.

Key facts

This page summarizes Alexander A. Fitzpatrick's Form 4 filing for Evofem Biosciences, Inc. (EVFM).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 23 Feb 2022, 15:08.

Change

Previous filing in this sequence was filed on 04 Jan 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EVFM transaction

Common Stock

Award

Transaction value: $0
Shares: +300,000
Change %: +139%
Price: $0.000000
Shares after: 516,422
Date: 18 Feb 2022
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EVFM transaction Derivative

Stock option (right to buy)

Award

Transaction value: $0
Shares: +300,000
Change %
Price: $0.000000
Shares after: 300,000
Date: 18 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 300,000
Exercise price: $0.4900
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The restricted stock awards will vest based on the Issuer's achievement of certain performance milestones in 2022.

Footnote F2

The shares of common stock exercisable pursuant to the option will vest in a series of forty-eight (48) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from February 18, 2022.